论文部分内容阅读
目的:比较阿奇霉素与红霉素对小儿支原体性肺炎患儿的临床疗效和安全性。方法:选取2015年2月—2016年2月期间收治的小儿支原体性肺炎患者78例,将其分为对照组和观察组,每组39例;对照组均给予红霉素治疗,观察组患者均给予阿奇霉素治疗,比较两组患者治疗后的总有效率和不良反应的发生率。结果:观察组患者临床治疗后的总有效率为94.87%高于对照组为74.36%(P<0.05);观察组患者用药期间不良反应的发生率为16.28%低于对照组为32.56%(P<0.05)。结论:采用阿奇霉素治疗小儿支原体性肺炎患者可显著改善患者临床症状,提高患者生存质量,降低不良反应的发生率,确保患者尽早恢复健康,其疗效优于红霉素的疗效。
Objective: To compare the clinical efficacy and safety of azithromycin and erythromycin in children with mycoplasmal pneumonia. Methods: 78 cases of children with mycoplasma pneumonia admitted from February 2015 to February 2016 were selected and divided into control group and observation group, 39 cases in each group. The control group were treated with erythromycin, and the observation group Were given azithromycin treatment, comparing the two groups of patients after treatment, the total effective rate and the incidence of adverse reactions. Results: The total effective rate of the observation group after treatment was 94.87%, which was 74.36% (P <0.05). The incidence of adverse reactions in the observation group was 16.28% less than that in the control group (P <0.05). Conclusion: Azithromycin in children with mycoplasma pneumonia can significantly improve clinical symptoms, improve patient quality of life, reduce the incidence of adverse reactions, to ensure that patients recover as soon as possible, its efficacy is superior to the efficacy of erythromycin.